CJC-1295 Side Effects in the Research Literature

I. · Adverse events reported in clinical trials

Adverse events reported in clinical trials

The CJC-1295 side effects most frequently logged across published Phase 1 and Phase 2 trials are local injection-site reactions, transient flushing, and headache [01][18]. Teichman 2006 reported that single ascending subcutaneous doses up to 250 mcg/kg in healthy adults were well tolerated, with injection-site reactions, flushing, and headache the most common adverse events; no serious adverse reactions were reported across the two ascending-dose trials [01]. The multiple-dose Phase 1 arm at weekly or biweekly 30-60 mcg/kg also reported subcutaneous administration safe and well tolerated [01].

The Phase 2 registered trial in HIV-associated visceral obesity (NCT00267527) used weekly escalating doses of 60-240 mcg/kg over twelve weeks in roughly 192 participants [18]. Injection-site reactions remained the most common local adverse event. The trial was halted in 2006 following a single participant fatality (myocardial infarction); the attending physician attributed the event to underlying coronary artery disease rather than the study drug, and no independent re-analysis of that determination has been published in peer-reviewed form [07]. Full Phase 2 adverse-event tables never appeared in the published literature.

II. · Water retention and edema in trials

Water retention and edema in trials

Mild peripheral edema is the class-level pharmacodynamic signature of GH-axis stimulation. Growth hormone increases renal tubular sodium reabsorption and expands extracellular fluid volume; transient edema is expected at any meaningful elevation of mean GH or IGF-1 [22]. Tesamorelin, the only FDA-approved GHRH(1-29) analog and the nearest structural cousin to CJC-1295, produced peripheral edema in approximately 6% of treated patients versus 2% on placebo in Phase 3 HIV-lipodystrophy trials [06]. The CJC-1295 Phase 1 and Phase 2 record noted mild edema in a subset of subjects, consistent with this class effect [06][18].

III. · What does the safety literature say?

What does the safety literature say?

The published Phase 1 and Phase 2 record on CJC-1295 is limited in both duration and population. Across roughly 28-day Phase 1 trials in healthy adults and a 12-week Phase 2 trial in HIV-lipodystrophy that did not complete enrollment, the short-term safety profile reported no serious adverse events attributable to the drug [01][18]. The compound is not FDA-approved for any indication, and the December 2024 Pharmacy Compounding Advisory Committee review concluded that the available evidence did not support inclusion on the 503A Bulks List [20]. Longer-term safety — at multi-year exposures, in non-healthy populations, with comorbidities — is unestablished in the public peer-reviewed record.

IV. · Long-term cancer signal: what is known and unkno

Long-term cancer signal: what is known and unknown

No published study has demonstrated a direct carcinogenic effect of CJC-1295 itself [21]. Long-term carcinogenicity has not been characterized in the public literature for this specific peptide [21]. Sustained IGF-1 elevation is a class-level theoretical concern across the GH/IGF-1 axis because IGF-1 has mitogenic signaling activity in many tissue types; this concern is noted in the broader GHRH-analog and GH-replacement literature rather than as a CJC-1295-specific finding [21]. Phase 3 data on tesamorelin showed no demonstrated increase in malignancy attributable to GHRH-axis stimulation at physiologic IGF-1 ranges over the trial windows studied [21].

V. · What the literature does not cover

What the literature does not cover

Several safety questions sit in the negative space of the published record. Multi-year safety in healthy adults has not been studied. Safety in adults with active malignancy, untreated diabetes, or significant cardiovascular disease has not been studied. Pregnancy and lactation exposure has not been studied. Interactions with other GH-axis modulators (recombinant GH, ghrelin-receptor agonists, somatostatin analogs) have been examined mechanistically [10] but not in long-duration safety trials. The Phase 2 termination preceded the kind of expanded safety surveillance that would have produced these data.

VI. · Editorial note on the discontinued program

Editorial note on the discontinued program

ConjuChem's broader DAC peptide program was wound down after the 2006 trial halt [07]. CJC-1295 itself was never independently linked to the fatality in published reporting; the attending physician's determination was pre-existing coronary artery disease [07]. But the silence that followed — no late-stage trials, no published Phase 2 efficacy data, no continued safety surveillance — is the editorial fact of this section. The published peer-reviewed safety record is what it is, and it ends in 2006.